Journal of Clinical Endocrinology & Metabolism, Vol 70, 642-646, Copyright © 1990 by Endocrine Society

ARTICLES

Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia

P Spritzer, L Billaud, JC Thalabard, P Birman, I Mowszowicz, MC Raux-Demay, F Clair, F Kuttenn and P Mauvais-Jarvis
Departement d'Endocrinologie et Medecine de la Reproduction, Laboratoire de Biochimie B, Hopital Necker, Paris.

Thirty late-onset adrenal hyperplasia patients consulting for isolated hirsutism were randomly divided into two groups; group 1 (n = 16) was treated with hydrocortisone in order to suppress androgen adrenal secretion, and group 2 (n = 14) received cyproterone acetate (CPA) antiandrogen therapy to inhibit peripheral androgen activity. The clinical and hormonal effects of each type of treatment were evaluated. Before treatment, the clinical and hormonal profiles of the two patient groups did not differ significantly. Excellent clinical evolution in terms of the regression of hirsutism was observed in the CPA-treated patients (54% decrease in the clinical score in 1 yr), in contrast with the slight decrease in hirsutism (26%) after hydrocortisone treatment. In hydrocortisone-treated patients, plasma androgen decreased to normal levels: testosterone from 3.05 +/- 1.45 to 1.46 +/- 0.42 nmol/L and delta 4-androstenedione from 13.6 +/- 4.1 to 6.33 +/- 1.47 nmol/L. Conversely, in CPA-treated patients, only a slight decrease in testosterone from 2.98 +/- 1.98 to 2.29 +/- 0.64 nmol/L and in delta 4- androstenedione from 12.9 +/- 5.9 to 9.86 +/- 2.23 nmol/L was observed. This slight decrease in plasma androgens contrasts with the rapid clinical improvement after CPA. These results emphasize the importance of peripheral receptivity to androgens in the clinical expression of hyperandrogenism. Moreover, they indicate that peripheral antiandrogen therapy may be more appropriate in late-onset adrenal hyperplasia patients than conventional adrenal inhibition using cortisone therapy.

This article has been cited by other articles:

				K. A. Martin, R. J. Chang, D. A. Ehrmann, L. Ibanez, R. A. Lobo, R. L. Rosenfield, J. Shapiro, V. M. Montori, and B. A. Swiglo Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1105 - 1120. [Abstract] [Full Text] [PDF]

				R. L. Barbieri Metformin for the Treatment of Polycystic Ovary Syndrome Obstet. Gynecol., April 1, 2003; 101(4): 785 - 793. [Abstract] [Full Text] [PDF]

				P.M. Spritzer, M. Poy, D. Wiltgen, L.S. Mylius, and E. Capp Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements Hum. Reprod., July 1, 2001; 16(7): 1340 - 1346. [Abstract] [Full Text] [PDF]

				C. Deneux, V. Tardy, A. Dib, E. Mornet, L. Billaud, D. Charron, Y. Morel, and F. Kuttenn Phenotype-Genotype Correlation in 56 Women with Nonclassical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 207 - 213. [Abstract] [Full Text]

				D. Deplewski and R. L. Rosenfield Role of Hormones in Pilosebaceous Unit Development Endocr. Rev., August 1, 2000; 21(4): 363 - 392. [Abstract] [Full Text] [PDF]

				P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, M. Caputo, E. Zanolin, and M. Muggeo Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 139 - 146. [Abstract] [Full Text]